Embargoed Until May 19, 2:45 p.m. CT

FOR MORE INFORMATION, CONTACT:

Dacia Morris
[email protected]
ATS Office 212-315-8620 (until May 16)

 

Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH
Abstract Presentation Time:  Sunday, May 19, 2:45 p.m. CT
Location: Room C147, 148 and154 (Level 1), Kay Bailey Hutchison Convention Center Dallas

 

TUMOR-SUPPRESSING PROTEIN MAY BE NOVEL TARGET IN PAH THERAPY

ATS 2019, Dallas, TX ─ In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.

VIEW ABSTRACT

CONTACT FOR MEDIA

Yuanjun Shen, PhD 
[email protected]

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

ATS 2019

TYPE OF ARTICLE
Research Results
SECTION
CHANNELS
Cardiovascular Health Respiratory Diseases and Disorders Medical Meetings
KEYWORDS
Pulmonary Arterial Hypertension Pulmonary Diseases Pulmonary Hypertension
COMMENTS | COMMENTING POLICY